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Objective. Prevotella copri, an intestinal microbe, may overexpand in stool samples from patients with newonset rheumatoid arthritis (RA), but it is not yet clear whether the organism has immune relevance in RA pathogenesis.
Methods. HLA-DR-presented peptides (T cell epitopes) from P copri were sought directly in the patients' synovial tissue or peripheral blood mononuclear cell (PBMC) samples using tandem mass spectrometry. The antigenicity of peptides or their source proteins was examined in samples from the RA patients or comparison groups. T cell reactivity was determined by enzyme-linked immunospot assay; antibody responses were measured by enzyme-linked immunosorbent assay, and cytokine/chemokine determinations were made by bead-based assays. Serum and synovial fluid samples were examined for 16S ribosomal DNA for P copri using nested polymerase chain reaction analysis.
Results. In PBMCs, we identified an HLA-DRpresented peptide from a 27-kd protein of P copri (Pcp27), which stimulated Th1 responses in 42% of patients with new-onset RA. In both new-onset RA patients and chronic RA patients, 1 subgroup had IgA antibody responses to either Pc-p27 or the whole organism, which correlated with Th17 cytokine responses and frequent anti-citrullinated protein antibodies (ACPAs). The other subgroup had IgG P copri antibodies, which were associated with Prevotella DNA in synovial fluid, P copri-specific Th1 responses, and less frequent ACPAs. In contrast, P copri antibody responses were rarely found in patients with other rheumatic diseases or in healthy controls.
Conclusion. Subgroups of RA patients have differential IgG or IgA immune reactivity with P copri, which appears to be specific for this disease. These observations provide evidence that P copri is immunerelevant in RA pathogenesis.
Rheumatoid arthritis (RA) results from a complex interplay between genetic and environmental factors (1, 2) . Great progress has been made in the identification of genetic factors and inflammatory pathways that influence the disease (1, 3) , but environmental factors are only now being determined (4) . A key hypothesis is that specific organisms in the mouth or microbiota in the gut, the composition of which is strongly influenced by environmental cues, may shape mucosal and systemic immune responses that affect joints in RA patients (4) (5) (6) (7) .
Using high-throughput sequencing, Scher et al (8) showed that Prevotella copri in the gut microbiota was overexpanded in stool samples from patients with new-onset RA compared with patients with chronic RA, patients with psoriatic arthritis, or healthy individuals. In new-onset RA patients, Prevotella abundance in the gut was at the expense of Bacteroides fragilis, an organism that is important for Treg function (9, 10) .
A second metagenome-wide analysis of fecal samples from RA patients showed dysbiosis in the gut as well as in the mouth and salivary glands (11) . Moreover, a recent study in mice showed that dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine (12) . However, it is unclear whether overexpansion of P copri in the human gut has the potential to affect immune cell functions at both mucosal and systemic sites, thereby contributing to RA disease pathogenesis.
Whereas the previous studies used unbiased, discovery-based approaches to assess dysbiosis of microorganisms in the oral or gut microbiome, we developed an unbiased, discovery-based approach to identify novel, immunogenic T cell epitopes in patients with chronic inflammatory arthritis. With this approach, in vivo HLA-DRpresented peptides are identified directly from patients' synovial tissue, synovial fluid mononuclear cells (SFMCs), or peripheral blood mononuclear cells (PBMCs) by liquid chromatography tandem mass spectrometry (LC-MS/MS) (13, 14) , followed by testing the antigenicity of identified peptides and their source proteins using patients' samples (15) (16) (17) (18) (19) .
Recently, we used this approach to search for T cell epitopes of proteins derived from microbes implicated in RA. We report here the identification of an HLA-DRpresented peptide (T cell epitope) derived from a P copri 27-kd protein (Pc-p27), which stimulated Th1 responses in 42% of RA patients. We then found that P copri induced differential antibody responses to this protein or the whole organism in a substantial portion of RA patients. These observations provide evidence of the immune relevance of P copri in the pathogenesis of RA.
PATIENTS AND METHODS
RA patients and control subjects. The study was approved by the Human Investigations Committee at Massachusetts General Hospital (MGH); all subjects gave written informed consent. All RA patients met the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for the disease (20) . All study patients with RA or other rheumatic diseases were recruited from the Rheumatology Clinic at MGH or from suburban MGH clinics.
We obtained synovial tissue, SFMCs, or PBMCs from 5 patients with RA to use for isolation of HLA-DR-presented peptides. To test implicated peptides and their source proteins for immunoreactivity in larger numbers of patients, we used our cohort of patients with new-onset RA from whom systematic clinical information, PBMCs, serum samples, and in some cases, SF samples were available. For comparison, PBMCs and serum samples were available from patients with Lyme arthritis. In addition, we used our cohort of patients with chronic RA from whom serum and sometimes SF samples were collected. Serum samples were obtained from patients with other types of arthritis or connective tissue diseases (CTDs) as well as from healthy control subjects. HLA-DR typing was performed on blood samples from RA patients at the American Red Cross Laboratory in Dedham, MA. Anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) determinations were made in the clinical laboratories at MGH.
Enzyme-linked immunospot (ELISpot) T cell assay. The detailed methods for isolation and identification of HLA-DRpresented peptides are described in our previous publication (13) . In the present study, 1 microbial peptide ( 2 KRIILILTVLLAMLG-QVAY 20 ) derived from a 27-kd P copri protein (WP_022121928.1) was identified in the PBMCs from 1 RA patient. This P copri peptide and 2 additional peptides from the same protein, which were predicted to be promiscuous T cell epitopes ( 52 DYRGYWT-MRYQFDSATVS 69 and 118 EKINSLPTSSTGI 130 ), were synthesized and purified by high-performance liquid chromatography in the Core Proteomics Laboratory at MGH. PBMCs from RA patients were then stimulated with the peptides (1 mM) in duplicate along with positive (phytohemagglutinin) and negative (no antigen) controls, and incubated for 5 days in culture at 378C in a 5% CO 2 incubator. Cells were then transferred to Dual-Color ELISpot plates coated with interferon-g (IFNg)/interleukin-17 (IL-17) antibodies (Cellular Technology Limited) and incubated overnight at 378C. Images of wells were captured using an ImmunoSpot series 3B analyzer, and spots were counted using ImmunoSpot software. A positive T cell response was defined as 3 SD above the mean value in healthy subjects.
Enzyme-linked immunosorbent assay (ELISA) for serum IgG and IgA antibodies to the P copri protein Pc-p27. ELISA plates were coated overnight at 48C with 0.25 mg/ml of the P copri protein Pc-p27 (GenScript). Afterwards, plates were incubated for 1 hour with blocking buffer (5% nonfat dry milk in phosphate buffered saline [PBS]-Tween). Each patient's serum sample (diluted 200-fold) was then added in duplicate wells for 1.5 hours, followed by horseradish peroxidase (HRP)-conjugated goat anti-human IgG (item sc-2453; Santa Cruz Biotechnology) or HRP-conjugated goat anti-human IgA (Bio-Rad) and then tetramethylbenzidine (TMB) substrate (BD). For interplate standardization, 2 control samples were included on each plate. In addition, using HeteroBlock (Omega Biologicals), we tested serum samples from 15 patients who had a range of optical density values on ELISA and confirmed that RF did not alter the ELISA results. Therefore, HeteroBlock was not used in subsequent antibody determinations.
ELISA for serum IgG and IgA antibodies to microbial organisms. The P copri type strain (DSM 18205) was obtained from the Leibniz Institute DSMZ, German Collection of Microorganisms and Cell Cultures. Bacteroides fragilis (ATCC 25285), Escherichia coli (ATCC 25922), and Porphyromonas gingivalis (ATCC 33277) isolates were obtained from the American Type Culture Collection. The bacterial cultures were inactivated in 1% formalin for 24 hours, washed twice in PBS, and diluted in PBS at a final concentration of 10 6 cells/ml. IgG and IgA antibody responses to whole-cell P copri, B fragilis, or E coli were determined by ELISA. The plates were coated overnight at 4˚C with suspensions of inactivated bacterial cells (10 6 cells/ml). Afterwards, plates were incubated for 1 hour with blocking buffer. Patients' serum samples (diluted 1:100) were added in duplicate wells for 1.5 hours, followed by HRPconjugated goat anti-human IgG or HRP-conjugated goat antihuman IgA and then TMB substrate. For interplate standardization, 2 control samples were included on each plate. The ELISA for P gingivalis was performed as previously described (21) .
Cytokine and chemokine determinations. The levels of 14 cytokines and chemokines associated with innate immune responses (IFNa, tumor necrosis factor, macrophage inflammatory protein 1a , and MIP-1b) and with Th1 (IFNg, IL-12, CXCL9, and CXCL10) or Th17 (IL-1b, IL-17A, IL-17E, IL-17F, IL-22, and IL-23) adaptive immune responses were determined in serum or SF samples from RA patients. Samples were diluted 1:5 in PBS and incubated with HeteroBlock at a concentration of 150 mg/ml to limit the possible confounding effects of RF. Protein levels of all 14 mediators of inflammation in serum or SF were assessed in 1 complete experiment using bead-based Luminex assays (EMDMillipore) coupled with a Luminex-200 System Analyzer. Data were assessed using xPonent 3.1 software.
Detection of P copri and B fragilis 16S ribosomal DNA (rDNA) in patient samples by polymerase chain reaction (PCR). DNA was isolated from 200 ml of serum or SF using a QIAamp DNA Mini kit (Qiagen). Nested PCR primers were designed to detect DNA for P copri or B fragilis 16S rDNA using Primer3 software (data not shown). DNA was amplified for outer PCR using species-specific forward and reverse primers; 1 ml of the amplified DNA (diluted 1:10 in sterile distilled water) was then used for the nested PCR reaction. All reactions were carried out using 2.5 units of HotStarTaq DNA polymerase (Qiagen). The amplification program included 40 cycles with denaturation at 948C for 30 seconds, annealing at 598C for 30 seconds, extension at 728C for 50 seconds, and a final extension for 10 minutes. For both outer and nested PCR reactions, a positive control (P copri or B fragilis DNA) and a negative control (sterile distilled water) were included. When sufficient DNA was available, samples were tested in duplicate. Amplified products (10 ml) were visualized by electrophoresis in a 2% agarose gel. The identity of the PCR products was validated by direct DNA sequencing, which was carried out at the Center for Computational and Integrative Biology DNA Core facility at MGH. The sequenced product was aligned with all human and known microbial genomes using Genomic Blast Sequence (NCBI).
Statistical analysis. Categorical data were analyzed by Fisher's exact test, and quantitative data were analyzed using unpaired t-test with Welch's correction. Correlations were sought using Pearson's correlation test. All analyses were performed using GraphPad Prism 6 software. All P values were two-tailed. P values less than or equal to 0.05 were considered statistically significant.
RESULTS
Identification of naturally presented, microbial HLA-DR-presented peptides. Using LC-MS/MS, we identified HLA-DR-presented peptides in synovial tissue (n 5 4), SFMCs (n 5 3), or PBMCs (n 5 2) from 5 patients with new-onset RA or chronic RA (14) . From the 17 HLA-DR-presented peptides identified in the PBMCs from 1 patient with chronic RA (patient RA1), 1 P copri sequence was found ( Figure 1A ). In contrast, no sequences from P gingivalis or from Borrelia burgdorferi, the agent of Lyme disease, were identified in any sample.
At disease onset, patient RA1, who had 2 copies of the RA shared epitope (HLA-DRB1*0401 and 0101), had severe symmetric polyarthritis of the large and small joints. During the course of the disease, tests for ACPAs, but not for RF, became positive. Despite treatment with disease-modifying antirheumatic drugs (DMARDs), she had recurrent episodes of knee swelling, with evidence of destructive changes in cartilage and bone. The HLA-DR-presented peptide derived from P copri was identified from PBMCs obtained during 1 such episode 7 years after disease onset.
The peptide sequence of 19 amino acids had 100% sequence homology with part of the signal sequence of a 27-kd protein of P copri (Pc-p27, WP_022121928.1) ( Figure  1A ). The peptide had minimal sequence homology with any human peptide, suggesting that it was not a human protein erroneously assigned with a microbial database. Using signalP 4.0 software (22) , this HLA-DR-presented P copri peptide was predicted to be part of the Sec secretion signal peptide sequence (D score 5 0.869), strongly suggesting that the peptide would be cleaved from the source protein. This signal peptide was not predicted to be lipidated (LipoP 1.0 Server). In addition, the algorithm TEPITOPE predicted that the peptide was highly promiscuous, as is typical of signal peptides, and would bind all 25 HLA-DR molecules modeled in the program (23) , including the patient's DRB1*0101 and 0401 molecules. When her PBMCs were stimulated with this P copri peptide in an IFNg ELISpot assay, her T cells secreted levels of IFNg that were .3 times the background levels (insert in Figure 1A ), attesting to the immunogenicity of the peptide.
T cell reactivity with P copri peptides in patients with new-onset RA. To determine the immunogenicity of HLA-DR-presented peptides of Pc-p27 more broadly, we used PBMCs obtained from our cohort of patients with new-onset RA who were seen prior to DMARD therapy, the time when immune responses would be expected to be most robust. All patients met the ACR/EULAR criteria for the disease (20) .
When PBMCs from 39 new-onset RA patients and from case patient RA1 (a patient with chronic RA) were stimulated with Pc-p27 peptide 1, a total of 17 of these 40 patients (42.5%) secreted levels of IFNg that were .3 SD above the mean value in healthy control subjects (P 5 0.0002), as determined with an IFNg/IL-17 doublecolor ELISpot assay ( Figure 1B) . In comparison, patients with Lyme arthritis lacked reactivity with this peptide (P , 0.0001). Stimulation of cells with phytohemagglutinin (used as a positive control) verified the viability of cells in all patients. The predominant response to stimulation with Pc-p27 in the RA patients was a Th1-type response, whereas PBMCs from only 1 RA patient secreted small amounts of IL-17 (data not shown). 966 PIANTA ET AL To determine whether patients had reactivity with other epitopes of the Pc-p27 protein, TEPITOPE was used to predict 2 additional promiscuous peptides derived from the same protein (Pc-p27 peptides 2 and 3). The 2 peptides together were predicted to be presented by all 25 HLA-DR molecules in the program, and therefore, these peptides were pooled for testing. PBMCs from 14 of the 40 patients (35%) secreted levels of IFNg to peptides 2 and 3 that were .3 SD above the mean value in healthy controls (P 5 0.0007) or in patients with Lyme arthritis (P 5 0.006) ( Figure 1C ). Altogether, PBMCs from 24 of the 40 patients (60%) had reactivity with 1 or more of the 3 P copri peptide sequences, showing that Th1 immune responses to this protein were common in new-onset RA patients. 20 was achieved by OMSSA and X!Tandem analysis. Inset, Findings of the interferon-g (IFNg) enzyme-linked immunospot (ELISpot) assay using matching peripheral blood mononuclear cells (PBMCs) from a patient with chronic rheumatoid arthritis (patient RA1) stimulated with the peptide (1, 2, and 4 mM). Reactivity of .3 times background (no antigen [Ag]) was considered positive. SFU 5 spot-forming units. B, Findings of the IFNg ELISpot assay using PBMCs from patients with RA, patients with Lyme arthritis (LA), and healthy control (HC) subjects. Cells were incubated with the HLA-DR-presented peptide identified from the PBMCs of patient RA1 (peptide 1; 1 mM). C, IFNg secretion of PBMCs from the same groups of patients and controls, incubated with 2 predicted promiscuous HLA-DR-binding peptides from Pc-p27 (1 mM each). A positive response was defined as a value .3 SD above the mean in healthy controls (area above the shaded region). In B and C, each symbol represents a single subject; horizontal lines show the mean. Star represents patient RA1. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.40003/abstract.
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Because of the importance of ACPAs in the diagnosis and pathogenesis of RA (1, 24) , peptide 1 was resynthesized with a citrulline in place of the only arginine in the peptide, which was predicted to be in the -P1-flanking position of the HLA-DR-binding pocket. However, the results suggested that the Pc-p27 signal peptide sequence was probably not citrullinated in vivo (data not shown). This does not preclude citrullination of other parts of the protein, including B cell epitopes.
IgG and IgA antibody responses to Pc-p27 and whole P copri. We next determined antibody responses to Pc-p27 in serum samples from 303 individuals. These included samples from 127 patients with new-onset or chronic RA, 28 patients with CTDs (14 with systemic lupus erythematosus, 4 with mixed CTD, 4 with scleroderma, and 6 with Sj€ ogren's syndrome), 28 patients with spondyloarthritides (SpA) (15 with psoriatic arthritis, 10 with ankylosing spondylitis, and 3 with reactive arthritis), 70 patients with Lyme arthritis, and 50 healthy subjects.
Of the 78 new-onset RA patients, 10 (13%) had IgG antibody responses to Pc-p27 that were .3 SD above those in healthy controls (P , 0.0001) (Figure 2A) . Moreover, 10 of 49 patients with chronic RA (20%) had IgG antibody responses to the protein (P , 0.0001), including patient RA1, in whom 4 serial samples obtained 4-9 years [CRA]) were tested for P copri antibodies. Enzyme-linked immunosorbent assays were performed to measure levels of IgG (A) and IgA (B) against the P copri 27-kd protein (Pc-p27) as well as levels of IgG (C) and IgA (D) against 1% formalin-inactivated P copri (whole organism). A positive response was defined as a value .3 SD above the mean in healthy controls (area above the shaded region). Each symbol represents a single subject; horizontal lines show the mean. Star represents patient RA1. Only significant P values relative to healthy controls are shown.
after disease onset yielded positive results. In contrast, only 1 patient with SpA and 1 healthy subject had borderline positive IgG antibody responses to the protein.
Because the first interactions between P copri and immune cells would presumably occur in the gut mucosa, we also determined IgA antibody responses to the organism. About 10% of the patients in both the new-onset RA and chronic RA groups had IgA antibody responses to Pc-p27 (P # 0.0002 and P # 0.02, respectively), and the responses tended to be more robust in those with newonset RA ( Figure 2B 
When both T and B cell responses were considered together, 3 of the 24 patients who had T cell reactivity with Pc-p27 peptides also had IgG Pc-p27 antibody responses, but none had IgA responses to the protein. In comparison, among 16 patients lacking T cell reactivity with Pc-p27 peptides, only 1 had an IgG antibody response to the protein, but 5 had IgA responses (P 5 0.05). The frequencies of shared epitope alleles in patients with P copri T cell or B cell responses was not significantly different from those in patients who lacked these responses (data not shown).
In an effort to confirm these findings, we determined IgG and IgA antibody responses to whole P copri using the same set of 303 serum samples. Using PCR, we confirmed that this strain expressed Pc-p27 (data not shown). Six of the 78 new-onset RA patients (8%) and 5 of the 49 chronic RA patients (10%) had IgG antibody responses to P copri (Figure 2C) . Similarly, 6 of 78 new-onset RA patients (8%) had IgA antibody responses to P copri (P # 0.004), and 7 of 49 patients with chronic RA (14%) had elevated IgA antibody levels to the organism (P # 0.002) ( Figure 2D ). Among the 19 patients who had positive IgG or IgA responses to P copri, only 5 (26%) had both responses. No patient with CTD, SpA, or Lyme arthritis had IgG or IgA antibodies to the organism. Altogether, 15% of 127 RA patients had P copri IgG or IgA antibody responses.
When the antibody responses to whole P copri or recombinant Pc-p27 were combined, 41 of the 127 RA patients (32%) had IgG or IgA antibody reactivity with the organism. Thus, antibody responses to P copri were common in RA patients, both early and late in the disease, yet they were rarely found in patients with other types of arthritis, implying specificity in RA.
Antibody responses to other oral or commensal bowel flora. To examine the specificity of antibody responses to P copri in RA patients, the same serum samples were also tested for reactivity with whole P gingivalis, an oral periodontal pathogen implicated in RA (25) , and with 2 common gut commensal organisms, Bacteroides fragilis and Escherichia coli.
Similar to previous studies (26, 27) , IgG antibody responses to P gingivalis were found in ;25% of our newonset RA and chronic RA patients, and these responses tended to be higher in RA patients than in the other comparison groups ( Figure 3A) . However, in contrast with P [CRA]) were tested for antibody responses to Porphyromonas gingivalis, Bacteroides fragilis, and Escherichia coli. Enzyme-linked immunosorbent assays (ELISAs) were performed to measure levels of IgG (A) and IgA (B) against P gingivalis, levels of IgG (C) and IgA (D) against B fragilis, as well as levels of IgG (E) and IgA (F) against E coli. All ELISAs used 1% formalin-inactivated bacteria. A positive response was defined as a value .2 SD (P gingivalis, as previously reported [26] ) or .3 SD (B fragilis and E coli) above the mean in healthy controls (area above the shaded region). Each symbol represents a single subject; horizontal lines show the mean. Only significant P values are shown.
copri antibody responses, IgG antibodies to P gingivalis were also present in small percentages of patients with other rheumatic diseases or in healthy control subjects, and IgA antibody reactivity with P gingivalis was not increased in RA patients compared with the other groups ( Figure  3B ). Moreover, in contrast with the dichotomy between IgG and IgA antibody responses to P copri, all RA patients with IgA antibodies to P gingivalis also had IgG responses to this microbe. Importantly, 66 of the 127 RA patients (52%) had antibody responses to either P copri or P gingivalis, but only 8 of the 66 patients (12%) had antibody responses to both microbes. Thus, minimal overlap was observed in the antibody responses to these 2 organisms, indicating that these responses are largely independent, and only the response to P copri was specific for RA.
Very few RA patients or those with other rheumatic diseases had IgG or IgA antibody responses to B fragilis or E coli that were .3 SD above the mean values in healthy control subjects (Figures 3C-F) . However, IgG absorbance values for B fragilis were significantly lower in new-onset RA patients than in patients in the other groups (P # 0.03) (Figure 3C ), consistent with the decrease in the abundance of B fragilis noted previously in new-onset RA patients (8) . Conversely, IgG and IgA absorbance values for B fragilis in the CTD group were significantly higher than those in the other groups. Thus, in contrast with P copri antibody responses, antibody levels to B fragilis and E coli were similar or lower in RA patients than in patients with other types of arthritis or in healthy subjects.
Clinical features of patients with P copri or P gingivalis antibody responses. Because P copri and P gingivalis have both been implicated in RA, we compared the clinical findings in our cohorts of new-onset and chronic RA patients who did or did not have IgG or IgA antibody responses to these microbes. Because the findings were similar in the 2 groups of RA patients, the groups were combined for presentation here. Several significant differences between these groups were found (Table 1) . First, 45 of the 50 patients (90%) with P copri antibody responses were female compared with 60 of the 86 patients (70%) who lacked such responses (P 5 0.006). In contrast, the percentages of female and male patients were not significantly different in those with P gingivalis antibody responses. Second, only 37% of the RA patients with IgG P copri antibody responses had ACPAs, compared with 74% of those who had IgA P copri antibodies (P 5 0.01) and 71% who lacked P copri antibodies (P 5 0.003). There was a similar trend with RF (P 5 0.08). In contrast, patients with P gingivalis IgG and IgA antibody responses had higher frequencies of ACPA and RF than did those who lacked these responses. Finally, at study entry, there was a trend toward higher disease activity scores (DAS28) in new-onset RA patients with either P copri or P gingivalis IgG antibody responses. There * Values for the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and Disease Activity Score in 28 joints (DAS28; using either the ESR or the CRP) were available only in patients with new-onset rheumatoid arthritis. RF 5 rheumatoid factor; ACPA 5 anti-citrullinated protein antibody. † P 5 0.006 versus the combined group of patients with IgG and patients with IgA P copri antibody responses. ‡ P 5 0.003 versus patients without P copri antibody responses (None). § P # 0.05 versus patients without P gingivalis antibody responses (None).
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PIANTA ET AL were no significant differences among the groups in age, body mass index, or smoking history. Thus, P copri antibodies were found primarily in women, and ACPAs were less common in patients with IgG P copri antibodies, whereas neither of these factors correlated with P gingivalis antibody responses, again indicating that these microbes induce distinct responses. Correlation of P copri antibodies with serum cytokine and chemokine levels. In an effort to link P copri with inflammatory responses and autoantibody production, IgG and IgA P copri antibody values were correlated with serum cytokine levels in 120 of the 127 RA patients in whom sufficient serum samples were still available. The 14 cytokines and chemokines measured were representative of innate, Th1, and Th17 immune responses. The assays were performed with HeteroBlock to limit possible interference by RF. Because the results were similar in new-onset RA and chronic RA patients, they were combined for presentation here.
When the magnitude of P copri IgG or IgA antibodies in the 37 antibody-positive patients were correlated with the cytokine levels, strong positive correlations were found between the IgA antibody values and the levels of 3 innate cytokines (IFNa, MIP-1a, and MIP-1b), 2 Th1-associated cytokines (IFNg and IL-12), and 3 Th17-associated cytokines (IL-17F, IL-22, and IL-1b) ( Figures  4A-C) . In contrast, IgG P copri antibody values correlated only with levels of the Th1 chemoattractant CXCL10 (Figure 4B) .
When P copri IgA absorbance values in all 120 RA patients, including those with positive and negative results, were correlated with the cytokine levels, even stronger associations were found with innate (MIP-1a and MIP1b), Th1 (IFNg and IL-12), and Th17 (IL-23, IL-22, IL- 17A, IL-17E, and IL-17F) cytokines (data not shown). In contrast, IgG absorbance values did not correlate with any cytokine or chemokine levels. Similarly, P gingivalis IgG and IgA antibodies did not correlate with any cytokine or chemokine level (data available upon request from the corresponding author), further indicating that these microbes induce distinct responses at different mucosal sites.
Detection of P copri 16S rDNA in synovial fluid. Because P copri IgG antibody responses were suggestive of a systemic immune response to the organism, we investigated whether P copri itself may spread to joints. For this purpose, we designed nested PCR primers to detect DNA for the 16S ribosomal RNA gene of P copri (16S rDNA) in patients' samples. Of 18 patients in whom paired serum and SF samples were available, 10 were obtained from new-onset RA patients and 8 were from chronic RA patients who were seen 3-50 years after disease onset. Five of the 18 patients had IgG antibody responses to P copri, 2 had IgA antibody reactivity with the organism, and 11 did not have P copri antibody responses. Although the numbers were small, the clinical correlations in each of these groups, including disease duration, DAS28 scores, and ACPA and RF frequencies, were similar to those in the larger groups of RA patients (data not shown).
Of the 5 patients with IgG P copri antibodies (patients RA1-RA5), P copri 16S rDNA was detected in SF from 3 of them. In 2 of these 3 patients, 16S rDNA was found in samples obtained prior to DMARD therapy. In the third patient (chronic RA patient RA1), in whom the original HLA-DR-presented P copri peptide was identified in PBMCs collected 7 years after disease onset ( Figure 1A ), P copri 16S rDNA was detected in SF obtained 9 years after disease onset ( Figure 5A ). In contrast, P copri DNA was not detected in SF samples from the remaining 13 patients: 2 with IgA P copri antibodies and 11 without P copri antibodies. Serum samples from all 18 patients had negative PCR results. Thus, 3 of the 5 patients with IgG P copri antibodies had positive PCR results for Prevotella DNA in SF as compared with none of 13 patients in the other 2 groups (P 5 0.01). 
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PIANTA ET AL For comparison, nested PCR primers were designed to detect 16S rDNA from B fragilis, another gut commensal. Of the 18 patients, 1 (patient RA15) had B fragilis 16S rDNA in SF; the sequence of this amplicon had 98% homology to B fragilis 16S rDNA (data not shown). This patient did not have positive findings on tests for P copri DNA or P copri antibody responses, and none of the 18 patients had IgG or IgA responses to B fragilis.
All positive results were confirmed by sequencing. Amplicons from patient RA2 had 100% identity with the sequence for P copri 16S rDNA in the NCBI database, which was obtained from a Japanese isolate. Interestingly, patient RA2 grew up in Korea. Amplicons from patient RA1 and from patient RA5 annealed with P copri sequences (DSM18205), but they had 86% and 89% sequence homology, respectively ( Figure 5B ), suggesting that the sequence could be from another Prevotella species ( Figure 5B ). Alternatively, even though cultures of P copri from stool samples were not available for analysis, the differences in P copri 16S rDNA sequences may be explained by strain variation, since the 3 patients grew up in widely different geographic locations (Korea, the US, or the Caribbean Islands). This is consistent with a study in which P copri was ranked as the second most-variable member of the human gut microbiota between continents (28).
DISCUSSION
In this study, using a discovery-based search for HLA-DR-presented peptides derived from P copri, 1 spectrum-to-peptide match was identified in PBMCs from 1 RA patient. This peptide sequence was found in the signal domain of a 27-kd protein of P copri, which was predicted to be a secreted protein. Signal sequences, which are cleaved prior to secretion, can accumulate in transmembrane locations; they are often highly antigenic, and they typically bind many different HLA-DR molecules (21) . In addition, the secreted portion of the protein may become an immunogenic soluble antigen (6, 29) . We then found that the signal sequence peptide and 2 other peptides from the Pc-p27 protein induced Th1 responses in 60% of patients with RA. Although RA shared epitope alleles have been reported to correlate inversely with P copri overexpansion in the gut (8), our study showed no significant correlations between these T cell epitopes and shared epitope alleles, which is consistent with the fact that these epitopes are promiscuous HLA-DR binders.
While PBMCs were available only from patients with new-onset RA, we were able to test for antibody responses to P copri in both new-onset RA and chronic RA patients. Although overexpansion of P copri was previously detected only in the stool of new-onset RA patients (8), we found similar frequencies of P copri antibody responses and similar clinical associations in new-onset RA and chronic RA patients, suggesting that once initiated, these antibody responses may persist for years. Importantly, in both patient groups, P copri antibody responses were specific for RA. First, P copri antibodies were rarely found in patients with other rheumatic diseases or in healthy controls. Second, antibody levels to 2 other gut commensals, B fragilis and E coli, were similar or lower in RA patients than those in patients with other arthritides or in healthy subjects. Third, there was little overlap between patients with P gingivalis antibodies and those with P copri antibodies.
P copri antibody responses were found primarily in women, both in those with new-onset RA and in those with chronic RA. When the 2 cohorts of patients were combined, P copri-negative patients had a sex ratio of 2.3 to 1 in favor of women, which is close to the ratio of 3 to 1 generally reported in RA cohorts. In contrast, the patients with P copri antibody responses had a sex ratio of 9 to 1, implying that this organism may be a substantial contributor to the female predominance in RA.
In mice, gut symbiotic gram-negative bacteria may disseminate systemically to other sites and induce IgG antibody responses (30) . These homeostatic IgG responses may help later in protecting against invasion by pathogenic gram-negative bacteria. Our studies showed high background values in E coli and B fragilis antibody assays, perhaps reflecting positive responses to these bacteria in some individuals. However, antibody responses to these bacteria were not higher in RA patients than in other comparison groups, including healthy controls, whereas P copri antibody responses were significantly higher in RA patients and correlated with inflammatory cytokine levels. Thus, our findings could not be explained simply by homeostatic P copri antibody responses.
The magnitude of IgA P copri antibody responses in RA patients in our study correlated with serum levels of a range of cytokines and chemokines associated with innate, Th1, and Th17 immune responses. Although we did not find Pc-p27-specific Th17 cells in PBMCs from these patients, it is likely that such cells were present in their intestinal mucosa. Th17 responses are presumably important initially in containing the organism in the bowel, but with chronic antigenic stimulation, they can promote systemic inflammation and autoimmunity (31) . This idea is supported here by strong correlations among IgA antibody values, serum levels of Th17-associated cytokines, and high frequencies of ACPAs, which could react with citrullinated proteins in joints (32) .
Conversely, other RA patients had IgG P copri antibody responses associated with Prevotella DNA in the joints, inflammatory Th1 responses, and infrequent ACPAs. We postulate that in these patients, P copri, a strict anaerobe, may spread systemically within phagocytic cells, including to the joints. In 2 of 3 patients, Prevotella DNA was detected in SF obtained early in the disease. However, in the remaining patient, in whom the Pc-p27 HLA-DR-presented peptide was identified in PBMCs obtained 7 years after disease onset (patient RA1), P copri DNA was detected in SF collected 9 years after disease onset. This suggests that P copri may spread from the bowel in repeated waves over a period of years, perhaps explaining the persistence of antibody responses to P copri in patients with chronic RA. The finding of 16S rDNA of B fragilis in the SF of 1 additional patient suggests that escape of other commensal bacteria from the bowel may occur, but this patient lacked an antibody response to the organism.
There are parallels between the potential role of P copri in RA pathogenesis and that of the periodontal pathogen P gingivalis (25, 33) . In patients with periodontitis, the composition of the oral flora shifts in favor of organisms, particularly anaerobes such as P gingivalis, that thrive in an inflammatory environment (34) . IgG antibody responses to P gingivalis in RA patients correlate strongly with systemic inflammation and coexistent periodontal disease (25, 27, 35) . Furthermore, P gingivalis may disseminate from the gingiva, presumably via dendritic cells, and lead to infection and inflammation at distant sites (6, 36) . DNA from periodontal bacteria has been detected by PCR in SF from a few RA patients with periodontal disease (37) .
In conclusion, our study provides evidence for the immune relevance of P copri in RA and suggests that bowel pathology may be a feature of the disease in this subgroup of patients. These new insights are likely to have implications for both the diagnosis and treatment of RA. For example, P copri IgG antibody responses could provide support for the diagnosis in RA patients who lack ACPA or RF. Moreover, dietary interventions or specifically tailored antibiotic regimens targeting P copri could play an adjunctive role to DMARDs in the treatment of this disease. Previously, patients with early RA who received tetracycline or its derivatives had significantly better outcomes than patients who received placebo (38, 39) . These results are often attributed to the antiinflammatory effects of tetracyclines, but recent insights about the microbiota suggest an additional explanation. Importantly, insights about specific immunerelevant commensal organisms in the microbiota promise a new era in the understanding and treatment of RA.
